This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia 2015; 29: 20–26.
Barosi G . Setting appropriate goals for the next generation of clinical trials in myelofibrosis. Curr Hematol Malig Rep 2015; 10: 362–369.
Barosi G, Tefferi A, Barbui T . Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? Leukemia 2012; 26: 1148–1149.
Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research And Treatment (IWG-MRT). Blood 2006; 108: 1497–1503.
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013; 122: 1395–1398.
Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res 2012; 36: 1500–1504.
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872–884.
Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007; 109: 1810–1816.
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
Cheson BD . Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 2015; 4: 5.
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691–4695.
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. 1. Blood 2006; 108: 419–425.
Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A et al. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Ann Hematol 2015; 95: 191–199.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Verstovsek S, Mesa RA, Gotlib J et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807.
Harrison C, Kiladjian JJ, Al-Ali HK et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787–798.
US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation, and Research (CDER) Center for Biologics Evaluation and Research (CBER) (2007). Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
US Food and Drug Administration. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Federal Register 2009; 74: 65132–133.
European Medicines Agency Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf (accessed 23 April 2015).
Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 2015; 1: 643–651.
Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 2015; 125: 2649–2655.
Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis:results of the UK ROBUST trial. Br J Haematol 2015; 170: 29–39.
Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S . The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 2015; 126: 1551–1554.
Angona A, Alvarez-Larrán A, Bellosillo B, Longarón R, Fernández-Rodríguez C, Besses C . Dynamics of JAK2 V617F allele burden of CD34(+) haematopoietic progenitor cells in patients treated with ruxolitinib. Br J Haematol 2015; 172: 639–642.
Breccia M, Molica M, Colafigli G, Alimena G . Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug? Expert Rev Hematol 2015; 8: 387–389.
Kremyanskaya M, Mascarenhas J, Rampal R, Hoffman R . Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. Br J Haematol 2014; 167: 144–146.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015; 100: 1139–1145.
Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9: 887–900.
Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117–1127.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 2015; 100: 479–488.
Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122: 4047–4053.
Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Tefferi A . Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. Leukemia 2015; 29: 498–500.
Fonseca E, Silver RT, Kazis LE, Iqbal SU, Rose M, Khan N . Ruxolitinib discontinuation in patients with myelofibrosis: an analysis from clinical practice. Blood 2013; 122: Abstract N.2833.
Le Tourneau C, Lee JJ, Siu LL . Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009; 101: 708–720.
Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J et al. Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. Haematologica 2015; 100: 690–695.
Pardanani A, Tefferi A . Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J 2014; 4: e268.
Profs Eli Estey (University of Washington) and Charles Bennett (Medical College S. Carolina) kindly reviewed the typescript. GB acknowledges support by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC, Milano) ‘Special Program Molecular Clinical Oncology 5 × 1000’ to AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative). A detailed description of the AGIMM project is available at http://www.progettoagimm.it. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.
GB participated in advisory boards of Novartis and Sanofi.
Rights and permissions
About this article
Cite this article
Barosi, G., Gale, R. How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?. Leukemia 30, 1453–1455 (2016). https://doi.org/10.1038/leu.2016.75